Ipamorelin and CJC-1295 are synthetic peptides that act on the growth hormone axis through two different receptors. Ipamorelin is a pentapeptide growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a); CJC-1295 is an analog of growth hormone-releasing hormone (GHRH) engineered for extended plasma residence. Laboratories studying pituitary signaling frequently compare the two because they reach the same endpoint — somatotroph activation — by separate upstream routes and on very different timescales. Understanding ipamorelin vs CJC-1295 at the receptor level helps researchers isolate which variable an experimental design is actually testing. Dynamite Research Peptides supplies both compounds with batch-specific third-party analysis, for research use only.
Research Background
Ipamorelin was first described by Raun and colleagues in 1998 in the European Journal of Endocrinology, where it was characterized as the first selective growth hormone secretagogue. Its sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — came out of a medicinal-chemistry program aimed at retaining growth hormone-releasing potency while reducing the corticotropin and prolactin responses seen with earlier growth hormone-releasing peptides.
CJC-1295 emerged later from work on extending peptide half-life. It is a modified GHRH(1-29) fragment; the version designated "with DAC" carries a Drug Affinity Complex — a maleimidopropionic acid linker that forms a covalent bond with circulating serum albumin. That bond shifts the peptide's residence time from minutes to days. A second version, CJC-1295 without DAC (often listed as mod GRF 1-29), omits the linker and behaves as a short-acting analog.
The ipamorelin vs CJC-1295 comparison therefore contrasts two distinct engineering strategies: receptor selectivity in one case, pharmacokinetic extension in the other.
Mechanism of Action
Ipamorelin binds GHS-R1a, a G protein-coupled receptor expressed on anterior pituitary somatotrophs. Receptor occupancy couples to Gq/11, activating phospholipase C, generating inositol trisphosphate and diacylglycerol, and mobilizing intracellular calcium. The calcium transient drives exocytosis of pre-formed growth hormone secretory granules. The published selectivity data are the reason ipamorelin is often chosen as a probe: in the original characterization it released growth hormone without the accompanying ACTH, cortisol, and prolactin elevations produced by comparator secretagogues.
CJC-1295 binds the GHRH receptor, a class B GPCR on the same cell population, but couples to Gs. That raises intracellular cAMP, activates protein kinase A, and phosphorylates CREB, increasing transcription at the growth hormone locus in addition to promoting release. With the DAC modification, albumin binding keeps the analog in circulation long enough to sustain that stimulus across days rather than minutes.
Both pathways converge downstream on hepatic JAK2-STAT5 signaling and IGF-1 transcription. The practical consequence for study design is temporal: ipamorelin vs CJC-1295 is largely a question of acute, pulsatile receptor activation versus prolonged, tonic stimulation.
Published Research Overview
The foundational ipamorelin reference remains Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH, "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, 1998;139(5):552-561. The paper reports in vitro and in vivo potency and, critically for later work, documents the compound's separation of growth hormone release from adrenal and prolactin axis activation.
For CJC-1295, the most-cited primary source is Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA, "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults," Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799-805. It reports two randomized, placebo-controlled, double-blind ascending-dose trials and establishes the extended pharmacokinetic profile that defines the DAC-modified analog.
Read together, these two papers frame the ipamorelin vs CJC-1295 comparison with primary data rather than inference: one establishes receptor selectivity, the other establishes duration of exposure. Researchers designing head-to-head work should consult both directly, along with current review literature on GHS-R1a and GHRH-receptor pharmacology, rather than relying on secondary summaries.
Storage & Handling
Both compounds ship as lyophilized powder. Store sealed vials at -20°C, desiccated and protected from light; lyophilized material is substantially more stable than material in solution. Reconstitute only when the sample is required for analysis, using an appropriate sterile diluent. Keep reconstituted aliquots refrigerated, minimize freeze-thaw cycles, and record reconstitution dates. Each Dynamite Research Peptides batch ships with a Certificate of Analysis documenting identity and purity.
Conclusion
Framing ipamorelin vs CJC-1295 as "which is better" misstates the question; they are tools for different experimental timescales and different receptors. Selection should follow from the study design — acute secretagogue response versus sustained GHRH-receptor stimulation. Whichever is chosen, reagent quality governs interpretability: HPLC and mass spectrometry data on the specific lot, not a generic specification sheet, are what let a result be attributed to the compound rather than to a contaminant.
Frequently Asked Questions
What purity documentation should accompany these compounds?
A lot-specific Certificate of Analysis reporting HPLC purity and mass-spectrometry identity confirmation. Generic or undated COAs are not traceable to the vial in hand and should be treated as insufficient.
Is CJC-1295 with DAC the same compound as CJC-1295 without DAC?
No. The DAC version carries the albumin-binding linker and has a markedly longer circulating half-life. The no-DAC version (mod GRF 1-29) is short-acting. Published pharmacokinetic data for one do not transfer to the other, and catalog listings should be read carefully.
Why are the two compounds studied together?
Because they activate the same cell population through different receptors, co-administration designs are used to probe whether the two signals are additive or redundant. That question is unresolved in the literature and remains an active area of preclinical investigation.
All products are for research use only — not for human or animal consumption.